AZD0292 Dose 2 for Healthy Participants

"Individuals aged 18 and above but below 60 are eligible for participation in this research."

"To be considered for this research study, individuals must meet stringent health criteria and fall within the age bracket of 18 to 60 years old. The trial is seeking approximately 24 eligible participants."

"The active recruitment of participants for this clinical trial, as detailed on clinicaltrials.gov, is currently paused. The study was first listed on 4th September 2024 and last revised on 3rd August 2024. Although enrollment is temporarily halted for this specific trial, there are alternative trials welcoming participants presently."

"The primary focus of this clinical investigation, spanning about Up to 13 weeks, is to determine the incidence of Adverse Events of Special Interest (AESI) among participants. Secondary endpoints include Area Under Concentration-Curve from Time Zero to the Last Quantifiable Concentration (AUClast), which involves evaluating the PK profile (AUClast) of AZD0292 after administering ascending IV doses to healthy adults; Number of Participants with Positive Anti-drug Antibodies (ADAs), focusing on ADA responses post-IV administration of escalating AZD0292 doses in healthy adult volunteers; and Area Under Concentration-Time Curve from Time Zero"

"Our team at Power has assessed the safety of AZD0292 Dose 1 to be a level 1 on our scale from 1 to 3. This determination is based on the Phase 1 nature of the trial, indicating scarce supportive data for both safety and efficacy."